Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ensitrelvir (S-217622) fumarate is a novel orally active inhibitor targeting the SARS-CoV-2 3CL protease (IC50 = 13 nM), demonstrating non-covalent and non-peptidic characteristics. This compound represents a pioneering advancement in the development of effective antiviral agents against the SARS-CoV-2 virus.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $53 | 5 days |
Description | Ensitrelvir (S-217622) fumarate is a novel orally active inhibitor targeting the SARS-CoV-2 3CL protease (IC50 = 13 nM), demonstrating non-covalent and non-peptidic characteristics. This compound represents a pioneering advancement in the development of effective antiviral agents against the SARS-CoV-2 virus. |
In vitro | In a cytopathic effect (cpe)-inhibition assay on VeroE6/TMPRSS2 cells infected with SARS-CoV-2, Ensitrelvir fumarate demonstrated EC50 values of approximately 0.4 μM for the wild-type virus and the Alpha, Beta, Gamma, and Delta variants, and EC50 values of 0.21 μM and 1.4 μM for SARS-CoV and MERS-CoV, respectively[1]. |
In vivo | Ensitrelvir fumarate effectively reduces SARS-CoV-2 replication within the lungs of mice in a dose-dependent manner[2]. |
Alias | S-217622 fumarate |
Molecular Weight | 647.96 |
Formula | C26H21ClF3N9O6 |
Cas No. | 2757470-18-9 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.